DEVELOPMENT OF MAPATUMUMAB, A FULLY HUMAN AGONISTIC MONOCLONAL ANTIBODY WHICH TARGETS AND ACTIVATES THE TRAIL-RECEPTOR-1

被引：0
|
作者：
Gallant, G. J. A. [1 ]
机构：
[1] Human Genome Sci, Rockville, MD USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [1] Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
    Greco, F. Anthony
    Bonomi, Philip
    Crawford, Jeffrey
    Kelly, Karen
    Oh, Yun
    Halpern, Wendy
    Lo, Larry
    Gallant, Gilles
    Klein, Jerry
    LUNG CANCER, 2008, 61 (01) : 82 - 90
  • [2] Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
    Mom, Constantijne H.
    Verweij, Jaap
    Oldenhuis, Corina N. A. M.
    Gietema, Jourik A.
    Fox, Norma Lynn
    Miceli, Rene
    Eskens, Ferry A. L. M.
    Loos, Walter J.
    de Vries, Elisabeth G. E.
    Sleijfer, Stefan
    CLINICAL CANCER RESEARCH, 2009, 15 (17) : 5584 - 5590
  • [3] Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 study in patients with advanced solid malignancies
    Mom, C. H.
    Sleijfer, S.
    Gietema, J. A.
    Fox, N. L.
    Piganeau, C.
    Lo, L.
    Uges, D. R. A.
    Loos, W.
    de Vries, E. G. E.
    Verweij, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 63 - 63
  • [4] Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
    T Trarbach
    M Moehler
    V Heinemann
    C-H Köhne
    M Przyborek
    C Schulz
    V Sneller
    G Gallant
    S Kanzler
    British Journal of Cancer, 2010, 102 : 506 - 512
  • [5] Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
    Trarbach, T.
    Moehler, M.
    Heinemann, V.
    Koehne, C-H
    Przyborek, M.
    Schulz, C.
    Sneller, V.
    Gallant, G.
    Kanzler, S.
    BRITISH JOURNAL OF CANCER, 2010, 102 (03) : 506 - 512
  • [6] Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: A Phase I Study (vol 15, pg 5584, 2009)
    Mom, C. H.
    Verweij, J.
    Oldenhuis, C. N. A. M.
    CLINICAL CANCER RESEARCH, 2009, 15 (21) : 6744 - 6744
  • [7] A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
    Hotte, Sebastien J.
    Hirte, Hal W.
    Chen, Eric X.
    Siu, Lillian L.
    Le, Lyly H.
    Corey, Alfred
    Iacobucci, Anne
    MacLean, Martha
    Lo, Larry
    Fox, Norma Lynn
    Oza, Amit M.
    CLINICAL CANCER RESEARCH, 2008, 14 (11) : 3450 - 3455
  • [8] A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin
    Oldenhuis, C.
    Mom, C.
    Sleijfer, S.
    Gietema, J. A.
    Fox, N. L.
    Corey, A.
    Eskens, F.
    Loos, W.
    de Vries, E. G.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control
    Bhaskar, Vinay
    Goldfine, Ira D.
    Bedinger, Daniel H.
    Lau, Angela
    Kuan, Hua F.
    Gross, Lisa M.
    Handa, Masahisa
    Maddux, Betty A.
    Watson, Susan R.
    Zhu, Shirley
    Narasimha, Ajay J.
    Levy, Raphael
    Webster, Lynn
    Wijesuriya, Sujeewa D.
    Liu, Naichi
    Wu, Xiaorong
    Chemla-Vogel, David
    Catarina Tran
    Lee, Steve R.
    Wong, Steve
    Wilcock, Diane
    White, Mark L.
    Corbin, John A.
    DIABETES, 2012, 61 (05) : 1263 - 1271
  • [10] Results of a phase 2 study of HGS-ETR1, a fully human agonistic monoclonal antibody to TRAIL Receptor 1, in subjects with relapsed or refractory colorectal cancer (CRC)
    Kanzler, S.
    Trarbach, T.
    Heinemann, V.
    Koehne, C. H.
    Sneller, V.
    Bieber, F.
    Galle, P. R.
    Seeber, S.
    EJC SUPPLEMENTS, 2005, 3 (02): : 178 - 178
12345